Answers are grounded in this paper and cite their sources.
Background/Objectives: Type 2 diabetes mellitus (T2DM) may impair bone healing after transforaminal lumbar interbody fusion (TLIF), but its association with solid interbody fusion in degenerative lumbar spondylolisthesis (DLS) remains uncertain. This study evaluated the association between T2DM and solid fusion and explored the associations of recombinant human bone morphogenetic protein-2 (rhBMP-2) augmentation with radiographic and functional outcomes. Methods: This retrospective cohort study screened 237 patients who underwent TLIF for DLS between April 2018 and March 2025; 97 were included in radiographic analyses and 93 in 12-month functional analyses. Solid fusion, the primary outcome, was defined as patient-level Brantigan–Steffee (BS) grade 5 on computed tomography obtained at least 6 months after surgery. Secondary outcomes included the Oswestry Disability Index (ODI), Barthel Index (BI), visual analogue scale (VAS), and minimal clinically important difference (MCID) achievement. Multivariable logistic regression was used to assess factors associated with solid fusion, with sensitivity analyses using Firth penalized logistic regression and exploratory analyses of the T2DM × rhBMP-2 interaction. Results: Twenty-one patients (21.6%) achieved BS grade 5 solid fusion. T2DM was independently associated with lower odds of solid fusion (OR 0.10, 95% CI 0.02–0.54; p = 0.007), whereas rhBMP-2 use was associated with higher odds (OR 5.58, 95% CI 1.74–17.86; p = 0.004). Firth analyses of the BS grade 5 endpoint yielded associations in the same direction. Among patients with T2DM, rhBMP-2 use was associated with lower ODI and higher BI scores at 12 months, including in baseline-adjusted sensitivity analyses, whereas VAS differences were not significant. ODI MCID achievement was 47.1% with rhBMP-2 and 33.3% without rhBMP-2; the corresponding VAS rates were 76.5% and 75.0%. Conclusions: T2DM was associated with lower odds of achieving BS grade 5 solid interbody fusion after TLIF for DLS. rhBMP-2 use was associated with higher odds of solid fusion and with better 12-month ODI and BI scores among patients with T2DM.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: